CCL7: A Potential Drug Target and Biomarker for Inflammatory Diseases
CCL7: A Potential Drug Target and Biomarker for Inflammatory Diseases
Introduction
The production and regulation of cytokines is a critical process in the immune system, which plays a crucial role in maintaining the balance of the immune response against pathogens and maintaining tissue homeostasis. Dysregulation of cytokine production and function can lead to the development of inflammatory diseases, such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and various types of cancer. One of the key cytokines involved in these processes is small-inducible cytokine A7 (CCL7), which has been identified as a drug potential target and biomarker for inflammatory diseases.
CCL7: biomarkers and drug targets
introduction
Generative and regulatory processes of the immune system play a critical role in sustaining immune responses against pathogens and maintaining tissue homeostasis. Immune dysregulation can lead to the development of inflammatory diseases such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and various cancers. One of the cytokines crucially involved in these processes is small inducible cytokine A7 (CCL7), which has been identified as a potential drug target and biomarker.
Function and mechanism of action of CCL7
CCL7 is a cytokine produced by monocytes and T cells. It plays an important role in cytokine networks and is a key player in multiple inflammatory responses and tumorigenesis. The main mechanism of action of CCL7 is to play a key role in inflammation and tissue repair processes by regulating the differentiation and function of immune cells.
The role of CCL7 in inflammatory response
CCL7 plays an important role in inflammatory responses, especially in the regulation of immune cell activity. Research shows that CCL7 can promote the activation and proliferation of monocytes and T cells, increase the production of inflammatory factors, and thus play a key role in the inflammatory response. CCL7 can also promote the release of cytokines, including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-伪 (TNF-伪), which are involved in inflammation. multiple steps in the reaction.
The role of CCL7 in tumorigenesis
CCL7 not only plays a role in inflammatory responses, but also plays an important role in tumorigenesis. Studies have shown that CCL7 can promote the invasion and metastasis of tumor cells and increase the vitality of tumor cells. CCL7 can also promote the generation and maintenance of tumor cells, thereby playing a key role in tumorigenesis.
Biological significance of CCL7
The biological significance of CCL7 is that, as a new immune evasion molecule, it can help tumor cells and inflammatory cells escape immune surveillance and attack, thus having broad application value in tumor and inflammation research. In addition, CCL7 is also closely related to the occurrence and development of various diseases, such as rheumatoid arthritis, COPD and various cancers. Therefore, CCL7 has broad application prospects as a new drug target and biomarker.
Clinical applications of CCL7
As a new drug target and biomarker, CCL7 has broad application prospects in tumor and inflammation research. At present, some studies have made certain progress in the relationship between CCL7 and tumors and inflammation. For example, some researchers have found that CCL7 is closely related to the onset and development of various cancers, such as lung cancer, breast cancer, and inflammatory bowel disease. In addition, some studies have also shown that CCL7 can predict the survival of tumor patients and serve as a new therapeutic target in tumor treatment.
Pharmacological significance of CCL7
As a new drug target and biomarker, CCL7 has broad application prospects in tumor and inflammation research. By inhibiting the biological activity of CCL7, a variety of inflammatory and tumor diseases can be effectively treated. For example, some researchers have found that anti-CCL7 drugs can significantly inhibit the production of inflammatory factors, thereby increasing the risk of inflammation.
Protein Name: C-C Motif Chemokine Ligand 7
Functions: Chemotactic factor that attracts monocytes and eosinophils, but not neutrophils. Augments monocyte anti-tumor activity. Also induces the release of gelatinase B. This protein can bind heparin. Binds to CCR1, CCR2 and CCR3
The "CCL7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL7 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D
